Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics

Ageing Research Reviews

Volumn 24, Issue , 2015, Pages 178-190

  Zhao, Liqin ^a,b   Woody, Sarah K ^a   Chhibber, Anindit ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer's disease; Apolipoprotein E; ER polymorphism; Estrogen receptor ; Late onset AD models; Sex differences

Indexed keywords

APOLIPOPROTEIN E; ESTROGEN RECEPTOR BETA; GESTAGEN; MF 101; PHYTOESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; AMNESIA; BREAST CANCER; COGNITIVE DEFECT; CONSTRUCT VALIDITY; DISEASE PREDISPOSITION; FACE VALIDITY; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PHENOTYPE; PREDICTIVE VALIDITY; REGULATORY MECHANISM; REVIEW; SEX DIFFERENCE; TREATMENT RESPONSE; BEHAVIORAL SCIENCE; BRAIN; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY;

AGING; ALZHEIMER DISEASE; BIOBEHAVIORAL SCIENCES; BRAIN; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; MALE; SEX FACTORS;

EID: 84961053896     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2015.08.001     Document Type: Review

References (161)

1. Adams M.M., Fink S.E., Shah R.A., Janssen W.G., Hayashi S., Milner T.A., McEwen B.S., Morrison J.H. Estrogen and aging affect the subcellular distribution of estrogen receptor-alpha in the hippocampus of female rats. J. Neurosci. 2002, 22:3608-3614.
2. Aguirre C., Jayaraman A., Pike C., Baudry M. Progesterone inhibits estrogen-mediated neuroprotection against excitotoxicity by down-regulating estrogen receptor-beta. J. Neurochem. 2010, 115:1277-1287.
3. Aguirre C.C., Baudry M. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. Eur. J. Neurosci. 2009, 29:447-454.
4. Altmann A., Tian L., Henderson V.W., Greicius M.D. Sex modifies the APOE-related risk of developing Alzheimer disease. Ann. Neurol. 2014, 75:563-573.
5. Artero S., Ancelin M.L., Portet F., Dupuy A., Berr C., Dartigues J.F., Tzourio C., Rouaud O., Poncet M., Pasquier F., Auriacombe S., Touchon J., Ritchie K. Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J. Neurol. Neurosurg. Psychiatry 2008, 79:979-984.
6. Bardin A., Boulle N., Lazennec G., Vignon F., Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 2004, 11:537-551.
7. Barnes L.L., Wilson R.S., Bienias J.L., Schneider J.A., Evans D.A., Bennett D.A. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 2005, 62:685-691.
8. Berti V., Mosconi L., Glodzik L., Li Y., Murray J., De Santi S., Pupi A., Tsui W., De Leon M.J. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol. Aging 2011, 32:2325. e2317-2326.
9. Binder D.K., Scharfman H.E. Brain-derived neurotrophic factor. Growth Factors 2004, 22:123-131.
10. Bretsky P.M., Buckwalter J.G., Seeman T.E., Miller C.A., Poirier J., Schellenberg G.D., Finch C.E., Henderson V.W. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1999, 13:216-221.
11. Brinton R.D. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann. N. Y. Acad. Sci. 2005, 1052:57-74.
12. Brinton R.D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. Trends Neurosci. 2008, 31:529-537.
13. Brinton R.D. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends Pharmacol. Sci. 2009, 30:212-222.
14. Brookmeyer R., Evans D.A., Hebert L., Langa K.M., Heeringa S.G., Plassman B.L., Kukull W.A. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement. 2011, 7:61-73.
15. Burkhardt M.S., Foster J.K., Laws S.M., Baker L.D., Craft S., Gandy S.E., Stuckey B.G., Clarnette R., Nolan D., Hewson-Bower B., Martins R.N. Oestrogen replacement therapy may improve memory functioning in the absence of APOE epsilon4. J. Alzheimer's Dis. 2004, 6:221-228.
16. Carter C.L., Resnick E.M., Mallampalli M., Kalbarczyk A. Sex and gender differences in Alzheimer's disease: recommendations for future research. J. Womens Health (Larchmt.) 2012, 21:1018-1023.
17. Chang Y.L., Fennema-Notestine C., Holland D., McEvoy L.K., Stricker N.H., Salmon D.P., Dale A.M., Bondi M.W., Alzheimer's Disease Neuroimaging Initiative APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. Alzheimers Dement. 2014, 10:336-348.
18. Chapman R.M., Mapstone M., Gardner M.N., Sandoval T.C., McCrary J.W., Guillily M.D., Reilly L.A., Degrush E. Women have farther to fall: gender differences between normal elderly and Alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in women. J. Int. Neuropsychol. Soc. 2011, 1-9.
19. Choi S.H., Kim Y.H., Hebisch M., Sliwinski C., Lee S., D'Avanzo C., Chen H., Hooli B., Asselin C., Muffat J., Klee J.B., Zhang C., Wainger B.J., Peitz M., Kovacs D.M., Woolf C.J., Wagner S.L., Tanzi R.E., Kim D.Y. A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 2014, 515:274-278.
20. Claxton A., Baker L.D., Wilkinson C.W., Trittschuh E.H., Chapman D., Watson G.S., Cholerton B., Plymate S.R., Arbuckle M., Craft S. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J. Alzheimers Dis. 2013, 35:789-797.
21. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
22. Day M., Sung A., Logue S., Bowlby M., Arias R. Beta estrogen receptor knockout (BERKO) mice present attenuated hippocampal CA1 long-term potentiation and related memory deficits in contextual fear conditioning. Behav. Brain Res. 2005, 164:128-131.
23. Dresner-Pollak R., Kinnar T., Friedlander Y., Sharon N., Rosenmann H., Pollak A. Estrogen receptor beta gene variant is associated with vascular dementia in elderly women. Genet. Test Mol. Biomark. 2009, 13:339-342.
24. Elcoroaristizabal Martin X., Fernandez Martinez M., Galdos Alcelay L., Molano Salazar A., Bereincua Gandarias R., Ingles Borda S., Gomez Busto F., Uterga Valiente J.M., Indakoetxea Juanbeltz B., Gomez Beldarrain M.A., de Pancorbo M.M. Progression from amnesic mild cognitive impairment to Alzheimer's disease: ESR1 and ESR2 polymorphisms and APOE gene. Dement. Geriatr. Cogn. Disord. 2011, 32:332-341.
25. Espeland M.A., Rapp S.R., Shumaker S.A., Brunner R., Manson J.E., Sherwin B.B., Hsia J., Margolis K.L., Hogan P.E., Wallace R., Dailey M., Freeman R., Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. J. Am. Med. Assoc. 2004, 291:2959-2968.
26. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J. Am. Med. Assoc. 1997, 278:1349-1356.
27. Fernandez-Martinez M., Elcoroaristizabal Martin X., Blanco Martin E., Galdos Alcelay L., Ugarriza Serrano I., Gomez Busto F., Alvarez-Alvarez M., Molano Salazar A., Bereincua Gandarias R., Ingles Borda S., Uterga Valiente J.M., Indakoetxea Juanbeltz B., Gomez Beldarrain M.A., Moraza Lopez J., Barandiaran Amillano M., de Pancorbo M.M. Oestrogen receptor polymorphisms are an associated risk factor for mild cognitive impairment and Alzheimer disease in women APOE (varepsilon)4 carriers: a case-control study. BMJ Open 2013, 3:e003200.
28. Forsell C., Enmark E., Axelman K., Blomberg M., Wahlund L.O., Gustafsson J.A., Lannfelt L. Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur. J. Hum. Genet. 2001, 9:802-804.
29. Fox E.M., Davis R.J., Shupnik M.A. ERbeta in breast cancer-onlooker, passive player, or active protector?. Steroids 2008, 73:1039-1051.
30. Franco R., Cedazo-Minguez A. Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?. Front. Pharmacol. 2014, 5:146.
31. Gallo D., De Stefano I., Grazia Prisco M., Scambia G., Ferrandina G. Estrogen receptor Beta in cancer: an attractive target for therapy. Curr. Pharm. Des. 2012, 18:2734-2757.
32. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
33. Gao S., Hendrie H.C., Hall K.S., Hui S. The relationship between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch. Gen. Psychiatry 1998, 55:809-815.
34. George S., Petit G.H., Gouras G.K., Brundin P., Olsson R. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor beta agonists moderate cognitive deficits and amyloid-beta levels in a mouse model of Alzheimer's disease. ACS Chem. Neurosc. 2013, 4:1537-1548.
35. Goumidi L., Dahlman-Wright K., Tapia-Paez I., Matsson H., Pasquier F., Amouyel P., Kere J., Lambert J.C., Meirhaeghe A. Study of estrogen receptor-alpha and receptor-beta gene polymorphisms on Alzheimer's disease. J. Alzheimers Dis. 2011, 26:431-439.
36. Grady D., Sawaya G.F., Johnson K.C., Koltun W., Hess R., Vittinghoff E., Kristof M., Tagliaferri M., Cohen I., Ensrud K.E. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009, 16:458-465.
37. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320:134-139.
38. Gustafsson J.A. What pharmacologists can learn from recent advances in estrogen signaling. Trends Pharmacol. Sci. 2003, 24:479-485.
39. Hall J.R., Vo H.T., Johnson L.A., Wiechmann A., O'Bryant S.E. Bonston naming test: gender differences in older adults with and without Alzheimer's dementia. Psychology 2012, 3:485-488.
40. Hartman J., Strom A., Gustafsson J.A. Estrogen receptor beta in breast cancer-diagnostic and therapeutic implications. Steroids 2009, 74:635-641.
41. Hartman J., Strom A., Gustafsson J.A. Current concepts and significance of estrogen receptor beta in prostate cancer. Steroids 2012, 77:1262-1266.
42. Hestiantoro A., Swaab D.F. Changes in estrogen receptor-alpha and -beta in the infundibular nucleus of the human hypothalamus are related to the occurrence of Alzheimer's disease neuropathology. J. Clin. Endocrinol. Metab. 2004, 89:1912-1925.
43. Honea R.A., Swerdlow R.H., Vidoni E.D., Burns J.M. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 2011, 76:822-829.
44. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3228-3233.
45. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
46. Irvine K., Laws K.R., Gale T.M., Kondel T.K. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J. Clin. Exp. Neuropsychol. 2012, 34:989-998.
47. Irvine K., Laws K.R., Gale T.M., Kondel T.K. Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis. J. Clin. Exp. Neuropsychol. 2012.
48. Jacobs E.G., Kroenke C., Lin J., Epel E.S., Kenna H.A., Blackburn E.H., Rasgon N.L. Accelerated cell aging in female APOE-epsilon4 carriers: implications for hormone therapy use. PLoS One 2013, 8:e54713.
49. Jacome L.F., Gautreaux C., Inagaki T., Mohan G., Alves S., Lubbers L.S., Luine V. Estradiol and ERbeta agonists enhance recognition memory, and DPN, an ERbeta agonist, alters brain monoamines. Neurobiol. Learn. Mem. 2010, 94:488-498.
50. Janicki S.C., Park N., Cheng R., Lee J.H., Schupf N., Clark L.N. Estrogen receptor beta variants modify risk for Alzheimer's disease in a multiethnic female cohort. J. Alzheimers Dis. 2014, 40:83-93.
51. Johnson J.K., McCleary R., Oshita M.H., Cotman C.W. Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res. 1998, 798:18-24.
52. Kalesnykas G., Roschier U., Puolivali J., Wang J., Miettinen R. The effect of aging on the subcellular distribution of estrogen receptor-alpha in the cholinergic neurons of transgenic and wild-type mice. Eur. J. Neurosci. 2005, 21:1437-1442.
53. Kang J.H., Grodstein F. Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline. Neurobiol. Aging 2012, 33:1129-1137.
54. Kennedy R.E., Cutter G.R., Schneider L.S. Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease. Alzheimers Dement. 2014, 10:349-359.
55. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
56. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:5925-5930.
57. Kunzler J., Youmans K.L., Yu C., Ladu M.J., Tai L.M. APOE modulates the effect of estrogen therapy on Abeta accumulation EFAD-Tg mice. Neurosci. Lett. 2014, 560:131-136.
58. Lambert J.C., Coyle N., Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease. J. Med. Genet. 2004, 41:104-112.
59. Lambert J.C., Harris J.M., Mann D., Lemmon H., Coates J., Cumming A., St-Clair D., Lendon C. Are the estrogen receptors involved in Alzheimer's disease?. Neurosci. Lett. 2001, 306:193-197.
60. Laurijssens B., Aujard F., Rahman A. Animal models of Alzheimer's disease and drug development. Drug Discov. Today Technol. 2013, 10:e319-e327.
61. Lee J.E., Han P.L. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. Exp. Neurobiol. 2013, 22:84-95.
62. Leitman D.C., Christians U. MF 101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms. Expert Opin. Investig. Drugs 2012.
63. Levin-Allerhand J., McEwen B.S., Lominska C.E., Lubahn D.B., Korach K.S., Smith J.D. Brain region-specific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. J. Neurochem. 2001, 79:796-803.
64. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
65. Liu F., Day M., Muniz L.C., Bitran D., Arias R., Revilla-Sanchez R., Grauer S., Zhang G., Kelley C., Pulito V., Sung A., Mervis R.F., Navarra R., Hirst W.D., Reinhart P.H., Marquis K.L., Moss S.J., Pangalos M.N., Brandon N.J. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat. Neurosci. 2008, 11:334-343.
66. Long J., He P., Shen Y., Li R. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor-beta. J. Alzheimers Dis. 2012, 30:545-558.
67. Lu B. BDNF and activity-dependent synaptic modulation. Learn. Mem. 2003, 10:86-98.
68. Luckhaus C., Spiegler C., Ibach B., Fischer P., Wichart I., Sterba N., Gatterer G., Rainer M., Jungwirth S., Huber K., Tragl K.H., Grunblatt E., Riederer P., Sand P.G. Estrogen receptor beta gene (ESRbeta) 3'-UTR variants in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:322-323.
69. MacLennan A.H., Henderson V.W., Paine B.J., Mathias J., Ramsay E.N., Ryan P., Stocks N.P., Taylor A.W. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause 2006, 13:28-36.
70. Manson J.E., Allison M.A., Rossouw J.E., Carr J.J., Langer R.D., Hsia J., Kuller L.H., Cochrane B.B., Hunt J.R., Ludlam S.E., Pettinger M.B., Gass M., Margolis K.L., Nathan L., Ockene J.K., Prentice R.L., Robbins J., Stefanick M.L. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 2007, 356:2591-2602.
71. McBride, R., September 14, 2012. Pharma counts just 3 Alzheimer's drug wins in 13 yeasr (101 losses). http://www.fiercebiotech.com/story/pharma-counts-just-3-alzheimers-drug-wins-13-years-101-losses/2012-09-14.
72. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 2002, 57:357-384.
73. McPherson S.J., Hussain S., Balanathan P., Hedwards S.L., Niranjan B., Grant M., Chandrasiri U.P., Toivanen R., Wang Y., Taylor R.A., Risbridger G.P. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3123-3128.
74. Mielke M.M., Leoutsakos J.M., Corcoran C.D., Green R.C., Norton M.C., Welsh-Bohmer K.A., Tschanz J.T., Lyketsos C.G. Effects of food and drug administration-approved medications for Alzheimer's disease on clinical progression. Alzheimers Dement. 2012, 8:180-187.
75. Milner T.A., McEwen B.S., Hayashi S., Li C.J., Reagan L.P., Alves S.E. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J. Comp. Neurol. 2001, 429:355-371.
76. Mortensen E.L., Hogh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 2001, 57:89-95.
77. Mosconi L., Berti V., Swerdlow R.H., Pupi A., Duara R., de Leon M. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum. Genom. 2010, 4:170-193.
78. Mosconi L., Sorbi S., de Leon M.J., Li Y., Nacmias B., Myoung P.S., Tsui W., Ginestroni A., Bessi V., Fayyazz M., Caffarra P., Pupi A. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 2006, 47:1778-1786.
79. Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 2012, 11:657-660.
80. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63:71-124.
81. Nathan B.P., Barsukova A.G., Shen F., McAsey M., Struble R.G. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology 2004, 145:3065-3073.
82. Neurology, A.A.O., 2007. Estrogen Use Before 65 Linked to Reduced Risk of Alzheimer's Disease. http://https://www.aan.com/PressRoom/Home/PressRelease/471.
83. Nilsen J., Brinton R.D. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:297-313.
84. Nilsen J., Deng J., Brinton R.D. Impact of clinically relevant progestins on the neural effects of estradiol and the signaling pathways involved. Drug News Perspect. 2005, 18:545-553.
85. Nilsson S., Koehler K.F., Gustafsson J.A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat. Rev. Drug Discov. 2011, 10:778-792.
86. Nishio M., Kuroki Y., Watanabe Y. Subcellular localization of estrogen receptor beta in mouse hippocampus. Neurosci. Lett. 2004, 355:109-112.
87. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006, 26:10129-10140.
88. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
89. Osterlund M.K., Grandien K., Keller E., Hurd Y.L. The human brain has distinct regional expression patterns of estrogen receptor alpha mRNA isoforms derived from alternative promoters. J. Neurochem. 2000, 75:1390-1397.
90. Osterlund M.K., Gustafsson J.A., Keller E., Hurd Y.L. Estrogen receptor beta (ERbeta) messenger ribonucleic acid (mRNA) expression within the human forebrain: distinct distribution pattern to ERalpha mRNA. J. Clin. Endocrinol. Metab. 2000, 85:3840-3846.
91. Payami H., Zareparsi S., Montee K.R., Sexton G.J., Kaye J.A., Bird T.D., Yu C.E., Wijsman E.M., Heston L.L., Litt M., Schellenberg G.D. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am. J. Hum. Genet. 1996, 58:803-811.
92. Pinton G., Brunelli E., Murer B., Puntoni R., Puntoni M., Fennell D.A., Gaudino G., Mutti L., Moro L. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res. 2009, 69:4598-4604.
93. Pinton G., Thomas W., Bellini P., Manente A.G., Favoni R.E., Harvey B.J., Mutti L., Moro L. Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One 2010, 5:e14110.
94. Pirskanen M., Hiltunen M., Mannermaa A., Helisalmi S., Lehtovirta M., Hanninen T., Soininen H. Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur. J. Hum. Genet. 2005, 13:1000-1006.
95. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
96. Prins G.S., Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73:233-244.
97. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L., Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J. Am. Med. Assoc. 2003, 289:2663-2672.
98. Regitz-Zagrosek V., Seeland U. Sex and gender differences in clinical medicine. Handb. Exp. Pharmacol. 2012, 3-22.
99. Rhodes M.E., Frye C.A. ERbeta-selective SERMs produce mnemonic-enhancing effects in the inhibitory avoidance and water maze tasks. Neurobiol. Learn. Mem. 2006, 85:183-191.
100. Rice, S., January 25, 2014. As drug trials fail, Alzheimer's researchers look toward prevention. http://www.modernhealthcare.com/article/20140125/MAGAZINE/301259969#.
101. Rissman E.F., Heck A.L., Leonard J.E., Shupnik M.A., Gustafsson J.A. Disruption of estrogen receptor beta gene impairs spatial learning in female mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3996-4001.
102. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., Ko M., LaCroix A.Z., Margolis K.L., Stefanick M.L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. J. Am. Med. Assoc. 2007, 297:1465-1477.
103. Ryan J., Carriere I., Amieva H., Rouaud O., Berr C., Ritchie K., Scarabin P.Y., Ancelin M.L. Prospective analysis of the association between estrogen receptor gene variants and the risk of cognitive decline in elderly women. Eur. Neuropsychopharmacol. 2013, 23:1763-1768.
104. Ryan J., Carriere I., Carcaillon L., Dartigues J.F., Auriacombe S., Rouaud O., Berr C., Ritchie K., Scarabin P.Y., Ancelin M.L. Estrogen receptor polymorphisms and incident dementia: the prospective 3C study. Alzheimers Dement. 2014, 10:27-35.
105. Ryan J., Carriere I., Scali J., Dartigues J.F., Tzourio C., Poncet M., Ritchie K., Ancelin M.L. Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study. Neurology 2009, 73:1729-1737.
106. Savaskan E., Olivieri G., Meier F., Ravid R., Muller-Spahn F. Hippocampal estrogen beta-receptor immunoreactivity is increased in Alzheimer's disease. Brain Res. 2001, 908:113-119.
107. Schmidt R., Kienbacher E., Benke T., Dal-Bianco P., Delazer M., Ladurner G., Jellinger K., Marksteiner J., Ransmayr G., Schmidt H., Stogmann E., Friedrich J., Wehringer C. Sex differences in Alzheimer's disease. Neuropsychiatric 2008, 22:1-15.
108. Schnabel, J., July 8, 2013. Why do all the large Alzheimer's drug trials fail? . http://www.dana.org/News/Why_Do_All_the_Large_Alzheimer_s_Drug_Trials_Fail_/.
109. Selfridge J.E., Lezi E., Lu J., Swerdlow R.H. Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol. Dis. 2013, 51:3-12.
110. Selman C., Tullet J.M., Wieser D., Irvine E., Lingard S.J., Choudhury A.I., Claret M., Al-Qassab H., Carmignac D., Ramadani F., Woods A., Robinson I.C., Schuster E., Batterham R.L., Kozma S.C., Thomas G., Carling D., Okkenhaug K., Thornton J.M., Partridge L., Gems D., Withers D.J. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009, 326:140-144.
111. Shumaker S.A., Legault C., Kuller L.H., Rapp S.R., Thal L., Lane D.S., Fillit H., Stefanick M.L., Hendrix S.L., Lewis C.E., Masaki K., Coker L.H. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. J. Am. Med. Assoc. 2004, 291:2947-2958.
112. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J. Am. Med. Assoc. 2003, 289:2651-2662.
113. Simpkins J.W., Dykens J.A. Mitochondrial mechanisms of estrogen neuroprotection. Brain Res. Rev. 2008, 57:421-430.
114. Simpkins J.W., Yang S.H., Wen Y., Singh M. Estrogens progestins, menopause and neurodegeneration: basic and clinical studies. Cell. Mol. Life Sci. 2005, 62:271-280.
115. Sohrabji F., Miranda R.C., Toran-Allerand C.D. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11110-11114.
116. Struble R.G., Cady C., Nathan B.P., McAsey M. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front. Biosci. 2008, 13:5387-5405.
117. Struble R.G., Rosario E.R., Kircher M.L., Ludwig S.M., McAdamis P.J., Watabe K., McAsey M.E., Cady C., Nathan B.P. Regionally specific modulation of brain apolipoprotein E in the mouse during the estrous cycle and by exogenous 17beta estradiol. Exp. Neurol. 2003, 183:638-644.
118. Swerdlow R.H., Burns J.M., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis:progress and perspectives. Biochim. Biophys. Acta 2013.
119. Tapia-Arancibia L., Aliaga E., Silhol M., Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res. Rev. 2008, 59:201-220.
120. Taylor A.H., Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J. Mol. Endocrinol. 2000, 24:145-155.
121. Thies W., Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208-245.
122. Tian Z., Fan J., Zhao Y., Bi S., Si L., Liu Q. Estrogen receptor beta treats Alzheimer's disease. Neural Regen. Res. 2013, 8:420-426.
123. Toran-Allerand C.D., Miranda R.C., Bentham W.D., Sohrabji F., Brown T.J., Hochberg R.B., MacLusky N.J. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4668-4672.
124. Ungar L., Altmann A., Greicius M.D. Apolipoprotein E, gender, and Alzheimer's disease: an overlooked, but potent and promising interaction. Brain Imaging Behav. 2014, 8:262-273.
125. Valen-Sendstad A., Engedal K., Stray-Pedersen B., Group A.S., Strobel C., Barnett L., Meyer N., Nurminemi M. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am. J. Geriatr. Psychiatry 2010, 18:11-20.
126. Walf A.A., Frye C.A. Administration of estrogen receptor beta-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. Pharmacol. Biochem. Behav. 2007, 86:407-414.
127. Walf A.A., Koonce C.J., Frye C.A. Estradiol or diarylpropionitrile decrease anxiety-like behavior of wildtype, but not estrogen receptor beta knockout, mice. Behav. Neurosci. 2008, 122:974-981.
128. Wang J.M., Irwin R.W., Brinton R.D. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:16983-16988.
129. Wang L., Andersson S., Warner M., Gustafsson J.A. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2792-2796.
130. Wang L., Andersson S., Warner M., Gustafsson J.A. Estrogen receptor (ER) beta knockout mice reveal a role for ERbeta in migration of cortical neurons in the developing brain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:703-708.
131. Ward A., Crean S., Mercaldi C.J., Collins J.M., Boyd D., Cook M.N., Arrighi H.M. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology 2012, 38:1-17.
132. Waters E.M., Yildirim M., Janssen W.G., Lou W.Y., McEwen B.S., Morrison J.H., Milner T.A. Estrogen and aging affect the synaptic distribution of estrogen receptor beta-immunoreactivity in the CA1 region of female rat hippocampus. Brain Res. 2011, 1379:86-97.
133. Weihua Z., Andersson S., Cheng G., Simpson E.R., Warner M., Gustafsson J.A. Update on estrogen signaling. FEBS Lett. 2003, 546:17-24.
134. Wilson M.E., Rosewell K.L., Kashon M.L., Shughrue P.J., Merchenthaler I., Wise P.M. Age differentially influences estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) gene expression in specific regions of the rat brain. Mech. Ageing Dev. 2002, 123:593-601.
135. Yaffe K., Cauley J., Sands L., Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch. Neurol. 1997, 54:1110-1114.
136. Yaffe K., Haan M., Byers A., Tangen C., Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000, 54:1949-1954.
137. Yaffe K., Lindquist K., Sen S., Cauley J., Ferrell R., Penninx B., Harris T., Li R., Cummings S.R. Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC Study. Neurobiol. Aging. 2009, 30:607-614.
138. Yamaguchi N., Yuri K. Changes in oestrogen receptor-beta mRNA expression in male rat brain with age. J. Neuroendocrinol. 2012, 24:310-318.
139. Yang S.H., Liu R., Perez E.J., Wen Y., Stevens S.M., Valencia T., Brun-Zinkernagel A.M., Prokai L., Will Y., Dykens J., Koulen P., Simpkins J.W. Mitochondrial localization of estrogen receptor beta. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4130-4135.
140. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
141. Yoshii A., Constantine-Paton M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol. 2010, 70:304-322.
142. Younes M., Honma N. Estrogen receptor beta. Arch. Pathol. Lab. Med. 2011, 135:63-66.
143. Yue Y., Hu L., Tian Q.J., Jiang J.M., Dong Y.L., Jin Z.Y., Cheng Y.H., Hong X., Ge Q.S., Zuo P.P. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol. Sin. 2007, 28:1129-1135.
144. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886.
145. Zandi P.P., Carlson M.C., Plassman B.L., Welsh-Bohmer K.A., Mayer L.S., Steffens D.C., Breitner J.C. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. J. Am. Med. Assoc. 2002, 288:2123-2129.
146. Zhao L., Brinton R.D. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases. J. Med. Chem. 2005, 48:3463-3466.
147. Zhao L., Brinton R.D. Estrogen receptor beta as a therapeutic target for promotion of neurogenesis and prevention of neurodegeneration. Drug Dev. Res. 2006, 66:103-117.
148. Zhao L., Brinton R.D. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci. 2006, 7:24.
149. Zhao L., Brinton R.D. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res. 2007, 1172:48-59.
150. Zhao L., Brinton R.D. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev. Neurother. 2007, 7:1549-1564.
151. Zhao L., Brinton R.D. In search of estrogen alternatives for the brain. Hormones, Cognition and Dementia: State of the Art and Emergent Therapeutic Strategies 2009, 93-100. Cambridge University Press, Cambridge, UK. E. Hogervorst, V.W. Henderson, R.B. Gibbs, R.D. Brinton (Eds.).
152. Zhao L., Jin C., Mao Z., Gopinathan M.B., Rehder K., Brinton R.D. Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator-a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons. J. Med. Chem. 2007, 50:4471-4481.
153. Zhao L., Mao Z., Brinton R.D. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology 2009, 150:770-783.
154. Zhao L., Mao Z., Chen S., Schneider L.S., Brinton R.D. Early intervention with an estrogen receptor beta-selective phytoestrogenic formulation prolongs survival, improves spatial recognition memory, and slows progression of amyloid pathology in a female mouse model of Alzheimer's disease. J. Alzheimers Dis. 2013, 37:403-419.
155. Zhao L., Mao Z., Schneider L.S., Brinton R.D. Estrogen receptor beta-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause. Menopause 2011, 18:1131-1142.
156. Zhao L., Morgan T.E., Mao Z., Lin S., Cadenas E., Finch C.E., Pike C.J., Mack W.J., Brinton R.D. Continuous versus cyclic progesterone exposure differentially regulates hippocampal gene expression and functional profiles. PLoS One 2012, 7:e31267.
157. Zhao L., O'Neill K., Brinton R.D. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res. Brain Res. Rev. 2005, 49:472-493.
158. Zhao L., O'Neill K., Brinton R.D. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J. Pharmacol. Exp. Ther. 2006, 319:1124-1132.
159. Zhao L., Wu T.W., Brinton R.D. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res. 2004, 1010:22-34.
160. Zhao L., Yao J., Mao Z., Chen S., Wang Y., Brinton R.D. 17beta-Estradiol regulates insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. Neurobiol. Aging 2011, 32:1949-1963.
161. Zhao Q., Lee J.H., Pang D., Temkin A., Park N., Janicki S.C., Zigman W.B., Silverman W., Tycko B., Schupf N. Estrogen receptor-Beta variants are associated with increased risk of Alzheimer's disease in women with down syndrome. Dement. Geriatr. Cogn. Disord. 2011, 32:241-249.